Objective To investigate the influence of cerebroside carnosine combined with intravenous thrombolysis with recombinant human tissue plasminogen activator (rt-PA) on serum high-sensitivity C reactive protein (hs-CRP) and insulin-like growth factor-1 (IGF-1) levels in patients with acute ischemic stroke.
Methods A total of 120 patients with acute ischemic stroke were selected and randomly divided into two groups, with 60 cases in each group. The control group was treated with rt-PA intravenous thrombolysis, while the study group was treated with cerebroside carnosine injection on the basis of the control group. The scores of Activities of Daily Living (ADL) and National Institutes of Health Stroke Scale (NIHSS), clinical efficacy, serum hs-CRP and IGF-1 levels, and the incidence rate of adverse reactions were compared between the two groups before and after treatment.
Results The total effective rate was 91.67% in the study group, which was significantly higher than 71.67% in the control group (P < 0.05). After treatment, the NIHSS score was significantly lower and ADL was significantly higher in both groups, and the scores in study group were significantly better than the control group (P < 0.05). After treatment, the levels of IGF-1 and hs-CRP in both groups were significantly higher than those before treatment, and the level of hs-CRP in the study group was significantly higher than that in the control group (P < 0.05). The incidence rate of adverse reactions in the study group was 15.00%, which showed no significant difference when compared to 11.67% in the control group (P>0.05).
Conclusion Application of rt-PA intravenous thrombolysis combined with cerebroside carnosine injection is safe and effective in the treatment of acute ischemic stroke, which can regulate the levels of serum hs-CRP and IGF-1, improve nerve function and daily living ability, and does not increase the incidence rate of adverse reactions.
DownLoad: